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Abstract
Background: Pilocytic astrocytomas occur predominantly in childhood. In contrast to the posterior fossa location,
hypothalamo-chiasmatic pilocytic astrocytomas display a worse prognosis often leading to multiple surgical
procedures and/or several lines of chemotherapy and radiotherapy to achieve long-term control. Hypothalamo-
chiasmatic pilocytic astrocytomas and cerebellar pilocytic astrocytomas have a distinctive gene signature and
several differential expressed genes (ICAM1, CRK, CD36, and IQGAP1) are targets for available drugs: fluvastatin
and/or celecoxib.
Results: Quantification by RT-Q-PCR of the expression of these genes was performed in a series of 51 pilocytic
astrocytomas and 10 glioblastomas: they were all significantly overexpressed in hypothalamo-chiasmatic pilocytic
astrocytomas relative to cerebellar pilocytic astrocytomas, and CRK and ICAM1 were significantly overexpressed in
pilocytic astrocytomas versus glioblastomas.
We used two commercially available glioblastoma cell lines and three pilocytic astrocytoma explant cultures to
investigate the effect of celecoxib/fluvastatin alone or in combination. Glioblastoma cell lines were sensitive to both
drugs and a combination of 100 μM celecoxib and 240 μM fluvastatin was the most synergistic. This synergistic
combination was used on the explant cultures and led to massive cell death of pilocytic astrocytoma cells.
As a proof of concept, a patient with a refractory multifocal pilocytic astrocytoma was successfully treated with the
fluvastatin/celecoxib combination used for 18 months. It was well tolerated and led to a partial tumor response.
Conclusion: This study reports evidence for new targets and synergistic effect of celecoxib/fluvastatin combination
in pilocytic astrocytoma. Because it is non-toxic, this new strategy offers hope for the treatment of patients with
refractory pilocytic astrocytoma.
Keywords: Hypothalamo-chiasmatic pilocytic astrocytoma, Celecoxib, Fluvastatin, Target gene, Synergy, Drug
repositioning, Metronomic chemotherapy
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Background
Pilocytic astrocytomas (PA) are the most frequent
gliomas in childhood. According to the World Health
Organization, most of them are grade I and are character-
ized by an excellent prognosis. PA arise preferentially in
the cerebellum, and the optic pathway. Other locations
such as brainstem, medulla or brain hemispheres are
also observed. Several clinico-pathological factors have
been associated with a negative impact on outcome.
They include incomplete surgery, the pilomyxoid vari-
ant astrocytomas (PMA grade II), young age and a
hypothalamo-chiasmatic (H/C) location [1-3]. H/C PA
usually carry a dismal prognosis with a high frequency
of relapse leading to iterative surgery, often associated
with further postoperative treatment that remains
poorly successful. The strong negative impact of the H/C
location on outcome is influenced by several factors
including inability to perform complete resection, the
high frequency of the PMA variant in this location and
the young age of the patients. Recent studies have
shown a wide range of mechanisms for deregulating the
ERK/MAPK pathway in PA, including NF1 deletion and
mutation, KIAA1549/BRAF fusion, SRGAP3/RAF1 fu-
sion and BRAF V600E activating mutation [4-6]. These
findings suggest that PA exhibiting BRAF alterations
might benefit from BRAF signalling pathway inhibitors.
However, not all PA demonstrate BRAF alterations and
could thus benefit from this kind of treatment. This is
particularly true for those arising in a H/C location, as
they show a lower frequency of BRAF alteration [5,7].
Given the chronic nature of PA in the H/C location,
there is a need for long term treatments that display low
toxicity and do not impair the patients’ quality of life by
further damaging cognitive function (especially in
young children) [8]. Therefore the treatment of H/C PA
still remains a major therapeutic challenge. Strategies
relying on metronomic chemotherapy [9] or drug repo-
sitioning [10] alone or in combination [11] seem to be
well suited for low grade glioma. Moreover, one im-
portant factor hampering the development of new
targeted therapies for these tumors is the relative lack
of cell lines derived from PA. Therefore, one aim of the
present study was to establish cell cultures of excised
tumor tissue from PA–bearing patients in order to
have suitable models to test their sensitivity against
various drugs.
We have previously reported that H/C PA have a gen-
etic signature distinct from that of their cerebellar
counterparts with a high expression of genes involved
in invasion and cell cycle [12]. Interestingly, among the
genes overexpressed in H/C PA, we found some genes
that are the targets of already available non-toxic drugs:
statins and celecoxib. These include CRK (v-crk avian
sarcoma virus CT10 oncogene homologue), CD36,
IQGAP1, and ICAM1. Celecoxib is a non-steroidal anti-
inflammatory drug which is an inhibitor of cyclooxygen-
ase 2 (COX-2). It has potent antitumor activity through
the induction of apoptosis [13] but can also act through
COX-2-independent mechanisms. It interferes with cellu-
lar adhesion machinery by dose-dependently decreasing
ICAM-1 and VCAM-1 expression in human colon adeno-
carcinoma HT29 cells [14]. It also promotes anoikis (cell
death secondary to the deregulation of focal adhesion
complexes and loss of cell attachment to the extracellular
matrix) by deregulating the focal adhesion assembly pro-
tein CRK-associated substrate P130CAS [15]. P130CAS is
a tyrosine-phosphorylated protein that interacts with the
SH2 domain of v-Crk [16].
The statins (3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors) are a class of drugs that in-
hibit the rate-limiting step in the cholesterol biosyn-
thetic pathway and are commonly used for the
treatment of hypercholesterolemia. However, increas-
ing clinical evidence suggests that statins can also be
used in cancer prevention and treatment [17,18].
The antitumor effect of statins is not fully elucidated
but involves major biological mechanisms such as in-
hibition of cell proliferation, promotion of apoptosis
and inhibition of angiogenesis [18]. Interestingly, one
of the statin targets is CD36, a scavenger receptor
that is expressed by numerous cells including plate-
lets, mononuclear phagocytes and endothelial cells
and that we have found highly expressed in H/C PA.
On microvascular endothelial cells, CD36 is a recep-
tor of thrombospondin-1 and functions as a negative
regulator of angiogenesis. On monocyte/macrophages
it is a receptor for long-chain fatty acids and facili-
tates their transport into the cells [19]. It has been
shown that pivastatin inhibits CD36 expression on
murine macrophages [20]. IQGAP1, one of the
IQGAP family members, binds to numerous proteins
involved in tumorigenesis including the RhoGTPases
Cdc42 and Rac1 that are also statin targets [21-23].
Lastly, statins can induce apoptosis via inhibition of
p-ERK1/2 pathway, which is activated in PA with
KIAA1549-BRAF fusion gene [24].
In the present study, we have confirmed the over-
expression of ICAM1, CRK, CD36, and IQGAP1 tran-
scripts in H/C PA versus cerebellar PA in a larger series
of tumors, and we also showed the expression of these
targets in GBM cell lines. Because of the lack of cell
lines derived from patients with PA, we have used two
GBM cell lines (U87-MG and U118) and a PA explant
model that we have previously described [25] to assess
the cytotoxic effect of fluvastatin and celecoxib and to
determine their synergistic effect. Lastly, we report the
anti-tumoral effect of celecoxib-fluvastatin combination
in a refractory multifocal PA in a child.
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Results
Expression of target genes of celecoxib and fluvastatin in
human tumors
ICAM1, CRK, CD36, IQGAP1 and COX2 genes have been
described in the literature as target genes for celecoxib
and fluvastatin drugs. Here we analyzed their expression
by RT-Q-PCR in a series of PA and GBM, in U87-MG
and U118 GBM cells lines, in the initial excised tumor of
three patients with PA from which we derived in vitro ex-
plants cultures, and in a surgical specimen from the case
report (arising from the second surgical resection because
mRNA obtained from the initial specimen was of poor
quality and not suitable for RT-Q-PCR).
Expression in H/C PA versus cerebellar PA : we con-
firmed in a larger cohort of tumors that the selected
transcripts showed higher ICAM1, CRK, CD36, and
IQGAP1 mRNA levels in H/C PA compared with cere-
bellar PA (p = 0.013, 0.027, 0.035 and 0.027 respectively)
(Figure 1a, Additional file 1a). Quantification of COX-2
mRNA revealed no significantly different mRNA levels
between these two PA sub-groups.
Expression in PA versus GBM: to go further, quanti-
fication of ICAM1, CRK, CD36, IQGAP1 and COX-2
transcripts was also performed in GBM. Results are
reported in Figure 1b and revealed higher ICAM1 and
CRK mRNA levels in PA compared to GBM samples
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Figure 1 Expression of transcripts in human tumors. Box plots of expression of transcripts in human tumors show significant differences in
(a) ICAM1 (p=0.013), CRK (p=0.027), CD36 (p=0.035) and IQGAP1 (p=0.027) mRNA expression values between hypothalamo-chiasmatic pilocytic
astrocytomas (H/C PA) and cerebellar PA and in (b) ICAM1 (p=0.002) and CRK (p<0.0001) mRNA expression values between glioblastomas (GBM)
and PA. The lower and upper edges of the box represent the first and third quartile respectively, while a horizontal line within the box indicates
the median. The vertical length of the box represents the interquartile range (IQR). The most extreme sample values (within a distance of 1.5 IQR
from the median) are the endpoints of the lines extending from the box. a.u.: arbitrary unit.
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(p = 0.002 and p < 0.0001 respectively) (see also Additional
file 1b). The remaining transcripts were not differentially
expressed.
Expression in U87-MG and U118 cell lines, PA-NAV,
PA-GAS and PA-PET initial tumor specimen and in the
excised tumor of the case report: we quantified the
ICAM1, CRK, CD36, and IQGAP1 mRNA expression in
our in vitro models and in the surgical specimen of the
case report. All transcripts were readily detected (see
Additional file 1c for detailed relative expression ratio
values).
Overall, these results showed that the target genes
ICAM1, CRK, CD36, and IQGAP1 were expressed as tran-
scripts in H/C PA but also, at lower levels, in cerebellar
PA and in GBM.
In vitro efficacy of the fluvastatin-celecoxib combination
in GBM human cell lines
Because of the lack of commercially available cell lines
derived from patients with PA, we used two GBM cell
lines (U87-MG and U118) expressing the target genes of
interest to assess the cytotoxic effect of fluvastatin and
celecoxib.
Our results revealed that the two GBM cell lines were
sensitive to both drugs. After a 48 h-treatment, IC50 values
of fluvastatin were 470 μM for U118 cell line (Figure 2a)
and 880 μM for U87-MG cell line (data not shown). IC50
values of celecoxib were 90 μM for U118 (Figure 2a) and
110 μM and U87-MG (data not shown). For the combin-
ation analysis, we first simultaneously incubated GBM
cells with a concentration of celecoxib next to IC50 values
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Figure 2 Cell growth activity measured by MTT assay on U118 cell line treated with drug combination. (a) U118 GBM cell line was
cultured with a range of various concentrations of fluvastatin or celecoxib either alone or in combination. After 48 hours, cell growth was
measured by MTT assay, and the concentration of each compound that induced 50% growth inhibition (IC50) was determined. U118 cell line was
sensitive to both drugs. Results represent the mean of four independent assays plus standard deviation. (b) After 48 hours, cytotoxicity was
measured by MTT assay. Fluvastatin (240 μM) potentiates the action of celecoxib (100 μM) on U87-MG and U118 cells causing massive cell
growth inhibition in both cell lines (99%) compared to fluvastin used alone (almost none) or celecoxib used alone (50%). Results represent the
mean of four independent assays plus standard deviation.
Mercurio et al. Acta Neuropathologica Communications 2013, 1:17 Page 4 of 14
http://www.actaneurocomms.org/content/1/1/17
(100 μM) and a concentration of fluvastatin that only
slightly affected cell growth when used alone (240 μM).
Interestingly, this co-treatment fully suppressed U118 and
U87-MG cell growth (up to 99%) as measured by the
MTT assay, showing that fluvastatin potentiated the cyto-
toxic effects of celecoxib in GBM human cells (Figure 2b).
GBM cell shrinkage and cell-adhesion-loss observed by
microscopy also confirmed the efficacy of such a combin-
ation (data not shown).
To further investigate the combination of celecoxib
and fluvastatin, growth inhibition assays were performed
on the two GBM cell lines after incubation with a range
of drug concentrations. Combination index (CI) values
were determined on the basis of the Chou and Talalay
method for all tested concentrations of chemotherapeutic
drugs, using Calcusyn® software (Table 1). In U87-MG
cells, the interaction between celecoxib and fluvastatin
was synergistic at all concentrations tested (CI<1), except
for the highest concentrations that resulted in additive
effects (CI=1). It can be noticed that the combination
between 100 μM celecoxib and 240 μM fluvastatin was
the most synergistic. Similar conclusions were found in
U118 cells: only lowest concentrations were antagonistic
while others mostly displayed synergistic effects.
To determine whether fluvastatin and celecoxib influ-
ence cell proliferation, the cell cycle was analyzed on
U87-MG. Upon combination of fluvastatin (240 μM)
and celecoxib (100 μM) treatment, cell cycle progression
is affected with a cell cycle arrest in G1 (Figure 3a).
Then, Ki67 staining was performed and results showed a
significant decrease of KI67-positive cells in treated cells
in comparison with control cells (p = 0,049) (Figure 3b,
A and B). Then, we determined whether cell death was
induced by the drug combination, by measuring
phosphatidylserine externalization using Annexin V, and
propidium iodide (PI) accumulation. As shown in Figure 3c,
the co-treatment with fluvastatin (240 μM) and celecoxib
(100 μM) for 24 h triggered apoptosis in U87-MG. Same
results have been obtained in U118 cells (data not shown).
Thus, the in vitro synergistic effects of celecoxib-
fluvastatin combination in human GBM cells rely on in-
duction of both apoptosis and cell proliferation decrease.
In vitro effects of fluvastatin and celecoxib on PA explant
cells
In this study, because PA cell lines were unavailable for
analysis, we made use of a PA explant culture model. Ex-
plant culture allows the maintenance of cells in their
microenvironment and, as we previously described [25],
it is highly accurate for the study of human brain gli-
omas because it recapitulates in vivo findings regarding
cell migration and cell proliferation.
Both drugs were tested on three PA explant cultures,
PA-NAV, PA-GAS and PA-PET with the drug alone
(100 μM of celecoxib or 240 μM of fluvastatin) or with
the synergistic combination found to be efficient with
the GBM cell lines (240 μM of fluvastatin and 100 μM
of celecoxib). As observed for GBM cell lines, we ob-
served effects on explants with different levels of degrad-
ation depending on the treatment. We have established
a 4 level scale: “unaffected” (explant), “affected +”,
“affected ++”, “detached” and we recorded the percent-
age of explants in each state for each condition. This ex-
periment was conducted in the three explant cultures
but was quantified in only one, PA-PET, described in
Figure 4a.
In untreated controls, explants and cell growth around
the explants were “unaffected” (Figure 4b, A). When
used alone, 240 μM fluvastatin treatment had little effect
on explants but most cells around them mainly became
round and lost their adhesion. This state represented the
state “affected +” (Figure 4b, D). Celecoxib treatment
(100 μM) mainly induced the “affected ++” state: damage
to both explants and cell growth (Figure 3b, E). Explants
treated with the combination (100 μM of celecoxib and
240 μM of fluvastatin) were totally disrupted and scattered,
and represented the “detached” state (Figure 3b, F).
These observations, validated in 3 different PA explant
cultures, confirmed that fluvastatin potentiated celecoxib
action leading to a massive induction of apoptosis in PA
cells.
Case report: treatment with the metronomic celecoxib/
fluvastatin combination
A 4 year old girl was referred to our department as she
developed a cachexia syndrome over several months. A
brain computed tomography scan demonstrated three
brain lesions: one in the suprasellar area, one in the third
ventricle area and one in an infratentorial area, together
with major hydrocephaly. Pathological examination of
surgical biopsies from the posterior fossa and 3rd ventricle
Table 1 Synergistic effects of fluvastatin and celecoxib
combination in U87-MG and U118 cell lines
U118 U87-MG
Fluvastatin (μM) 240 480 240 480
Celecoxib (μM)
50 >1 0, 444 0,498 0,417
80 >1 0,339 0,458 0,296
100 0,345 0,375 0,009 0,368
130 0,889 0,824 0,057 0,491
260 0,445 +/-1 0,115 +/-1
Growth inhibition assays were performed on U87-MG and U118 cell lines
using the MTT assay after 48 h incubation with a range of concentrations of
fluvastatin and celecoxib. The combination index (CI) of fluvastatin and
celecoxib was calculated using the median effect method (Chou and Talalay
method). CI values less than 1 indicate synergy, CI equal to 1 indicates an
additive affect, and CI greater than 1 indicates antagonism between the two
drug agents.
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Figure 3 (See legend on next page).
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demonstrated a PA, with KIAA1549-BRAF fusion but no
BRAFV600E mutation.
Complete surgical resection was not indicated and she
underwent chemotherapy according to the BB-SFOP
protocol [26] from June 2002 to October 2003. After
initial stabilization, in 2004, a control MRI (magnetic
resonance imaging) demonstrated tumor progression in
the 3rd ventricle and the appearance of medullar metas-
tasis. In January 2008, 4 years after completion of treat-
ment, she demonstrated local tumor progression of 3
lesions together with a major infiltration of the brain-
stem. The three tumors then grew further and turned
into a real H/C tumor. She then received 7 cycles of oral
temozolomide [27] that failed to control the disease. In
July 2008, she underwent a partial surgical resection. In
December 2008, she developed a new local and spinal
progression and was treated according to standard
chemotherapy published by Packer and colleagues [28]
but developed a severe carboplatin allergic reaction after
the first carboplatin infusion leading to cessation of the
treatment. Because the parents refused standard alterna-
tive treatment requiring intraveinous drugs and because
there was no short term functional risk, we proposed to
initiate in 2009 a new strategy relying on the combin-
ation of fluvastatin and celecoxib based on preclinical
and previous clinical reports. Celexoxib was adminis-
tered per os at the dose of 200 mg twice daily as pub-
lished in several metronomic paediatric protocols [29,30]
and fluvastatin per os once daily for 2 weeks every
4 weeks with increasing dosage starting at 2 mg/kg/day
to 8 mg/kg/day [31].
After fluvastatin/celecoxib administration, control
MRI performed every 6 months for an 18 month period
demonstrated a progressive significant decrease in size
of the enhancement area (Figure 5). Because the patient
was stabilized, treatment was stopped.
However, eight months after stopping treatment, a
degradation of her neurological status was observed.
The cerebral and spinal MRI did not show any progres-
sion of the disease. Surgery was not feasible and the par-
ents ruled out radiotherapy. Thus in September 2011,
because her neurological status worsened, it was decided
to initiate a new relevant treatment, at parents’ request,
with the combination of irinotecan-bevacizumab, to
avoid radiotherapy and aim at a rapid response as re-
cently described [32]. Clinical improvement was noted
after a month and she is now able to walk again with a
decrease in size of the tumor.
Discussion
On the basis of gene expression data, in vitro and pre-
liminary clinical data, we report here the potential use of
fluvastatin, a cholesterol lowering agent, and celecoxib,
an anti-inflammatory agent, in the clinical management
of PA refractory to conventional treatments.
The treatment of some PA, especially H/C PA, usually
requires multiple surgery and/or several lines of chemo-
therapy and/or radiotherapy to achieve long term
control [2]. The intrinsic toxicity of chemotherapy con-
tributes to the burden of treatment and more specific-
ally to the neurocognitive alteration of these patients.
As proposed recently, new modalities of treatment rely-
ing on metronomic scheduling [9] and drug reposi-
tioning can lead to long term treatment that could turn
malignant disease in chronic disease while displaying
only limited toxicity [33,34].
We have previously reported that H/C PA have a dis-
tinct genetic signature, as compared to their cerebellar
counterparts, with a high expression of genes involved in
invasion and cell cycle [12]. Among the over-expressed
genes in H/C PA, we found that CRK, CD36, IQGAP1 and
ICAM1, could be targeted by already available non-toxic
drugs such as statins and celecoxib. These compounds
were not initially used as anticancer agents, but drug repo-
sitioning studies, that aim at unveiling new therapeutic
properties for “old” agents, revealed their anticancer
effects [18,35].
Celecoxib is a non-steroidal anti-inflammatory drug
that is an inhibitor of cyclooxygenase 2 (COX-2) and has
many anticancer properties. Interestingly, celecoxib has
already been used in several clinical studies including
paediatric metronomic protocols [29,30]. Our in vitro
(See figure on previous page).
Figure 3 Effect of fluvastatin and celecoxib on U87-MG cell cycle, proliferation and apoptosis. (a) Cells were treated for 24 hours with
240 μM fluvastatin/100 μM celecoxib. Cell cycle of control and treated cells was analyzed by FACS using propidium-iodide-stained nuclei.
Percentage of cells in G1, S and G2 phases is shown. (b) Cells were treated for 24 hours with 240 μM fluvastatin/100 μM Celecoxib. Cell
proliferation was analyzed by FACS using KI67 staining. (A) Representative experiment of 3 independent experiments is shown. (B) The
percentage of KI67-positive cells with mean plus standard deviation of 3 independent experiments is shown. (c) U87-MG cell lines were cultured
with fluvastatin (240 μM) or celecoxib (100 μM) either alone or in combination. After 24 hours, cells were collected and analyzed for fluorescein
annexin-V and propidium iodide (PI) labelling by FACS in order to distinguish and quantitatively analyze non-apoptotic cells (Annexin-V negative/
PI negative, lower-left), early apoptotic cells (Annexin -V positive/PI negative, lower-right), late apoptotic/necrotic cells (Annexin-V positive/PI
positive, upper-right) and dead cells (Annexin V negative/PI positive, upper-left). This double-labelling was performed on untreated cells and
treated cells with the drug combination (100 μM of celecoxib/240 μM of fluvastatin).
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data confirms these findings as celecoxib demonstrates
anti-tumor activity in 2 GBM cell lines and 3 PA explants
cultures.
Fluvastatin was also identified as a drug that could
target genes of interest and therefore we hypothesized
that it could be another potential agent for the treatment
of H/C PA. Our in vitro data confirmed our hypothesis
showing activity with IC50 in the range of 500 μM to
900 μM for GBM. This result is in accordance with pre-
vious studies reporting the effect of celecoxib in other
GBM cell lines [36-38]. Most interestingly, a previous
paediatric phase I study determined the maximum toler-
ated dose of fluvastatin given for 14 days every 4 weeks
and reported disease stabilization for over 20 months in
2 of the 5 patients with anaplasic astrocytoma [31].
Ferris and colleagues also conducted a case–control
study to investigate statin and/or non-steroidal anti-
inflammatory drug (NSAID) therapy and risk of glioma
[23,39]. They reported that the use of statin and NSAID
was also significantly inversely related to glioma risk,
confirming the role of Ras/Rho GTPases or inflammatory
cytokines in gliomagenesis.
The combination of celecoxib and fluvastatin re-
vealed strong synergy when evaluating their role
in vitro, since, using the Chou and Talalay method,
the obtained CI was <1. Indeed, combining the IC50
celecoxib concentration with a concentration of fluva-
statin below the single drug IC50 triggered massive cell
death (approximately 99%), therefore strengthening the
potential interest of this combination.
Steady state plasma levels of celecoxib following
twice daily 250 mg/m2 celecoxib intake in children led
to peak concentrations of 1400 μg/L +/− 700 and
2800 μg/L +/− 1500 respectively if celecoxib was taken
without or with food [40]. Siekmeier and colleagues
[41] reported that fluvastatin levels following standard
(1 to 2 mg/kg/day) doses could reach 100 μg/L. Since
increasing doses lead to increased peak and area under
curve (AUC), the fluvastatin doses (8 mg/kg/day)
recommended by the phase I trial indicate that IC50
concentrations of fluvastatin are clinically achievable.
In addition, Sierra and colleagues [42] and Dembo and
colleagues [43] have respectively shown that statins (in-
cluding fluvastatin) and COX-2 inhibitors (including
celecoxib), could penetrate blood–brain-barrier and reach
the central nervous system.
Given that both celecoxib and fluvastatin had already
been used in children with cancer, that their combin-
ation might be synergistic [44] and had already been
tested in vitro and in vivo in other tumor models
[45,46], we decided to use this combination for a teenage
girl with a refractory relapsing multifocal PA. She had
(See figure on previous page).
Figure 4 In vitro analysis of the cytotoxicity of fluvastatin and/or celecoxib on PA explant cultures. PA explants were grown in DMEM
10% FCS for 10 days and then treated with fluvastatin (240 μM) or celecoxib (100 μM) either alone or in combination. Untreated explants were
used as controls. (a) Regarding the 4 level scale that we have established (“unaffected”, “affected +”, “affected ++”, “detached”), we recorded the
percentage of explants in each state for each condition in PA-PET explant culture. (b) Ten days after explantation, cell growth was observed
around the explants and in untreated conditions, explants and cell growth around the explants were “unaffected” (A). Expression of GFAP (B) and
A2B5 (C) was analyzed by immunofluorescent staining to confirm the glial nature of cultured cells. When used alone, 240 μM fluvastatin
treatment had little effect on explants but most cells around them mainly became round and lost their adhesion (D, “affected +” state). Celecoxib
treatment (100 μM) mainly induced the “affected ++” state: damage to both explants and cell growth (E). Explants treated with the combination
were totally disrupted and scattered (F, “detached” state). Scale bar: 100 μm.
(a) (b)
Figure 5 Cerebral MRI, sagittal sections, T1 weighted with gadolinium injection. (a) May 2009: Before antitumoral treatment with celecoxib/
fluvastatin. Hypersignal in the hypothalamo-chiasmatic region, fourth ventricle, cerebellum. Post-operative reshuffle of the posterior fossa.
(b) September 2010: After 16 months of antitumoral treatment with celecoxib/fluvastatin. Decrease in contrast enhancement of the hypothalamo-
chiasmatic, fourth ventricle and cerebellum lesions.
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previously refused standard cytotoxic chemotherapy fol-
lowing several lines of treatment with limited success
and severe carboplatin allergy. While the celecoxib/
fluvastatin combination was effective on the H/C lesion
after several months of treatment with a progressive
decrease in contrast enhancement that was evidenced
on MRI, no similar effect was obtained on the spinal
metastasis. These differences in anti-tumoral effect
might be explained by tumor heterogeneity between the
primary tumor and spinal metastasis. Alternatively, both
agents can display anti-angiogenic properties and the re-
duction in contrast enhancement in the primary lesion
suggests that the celecoxib/fluvastatin combination may
at least in part work through angiogenesis inhibition.
Therefore, different tumoral angiogenic patterns may be
associated with different localizations of the disease.
Lastly, if the tumoral microenvironment can change
upon localization in the tumor, the inflammatory infil-
trate in the primary tumor may be more senstitive to the
anti-inflammatory effect of the metronomic treatment.
Although a spontaneous decrease in size of the low
grade glioma could not be ruled out, epidemiological,
genetic and functional data indicate a potential role for
combined therapy of fluvastatin and celecoxib in the
treatment of refractory relapsing multifocal PA.
Conclusion
In conclusion, on the basis of genetic data, we identified
genes that are differentially expressed in H/C PA versus
cerebellar PA, but also in PA versus GBM. We then
tested in vitro the single drug and combination effects of
fluvastatin and celecoxib on both GBM cell lines and PA
explant cultures. This strategy led to the identification of
potentially new, non-toxic, long-term treatments for pa-
tients with refractory PA, whatever their location. More
experiments are mandatory to explore the underlying
mechanism of action of this combination. A phase I trial
establishing the maximum tolerated dose of this com-
bination in children with H/C PA is planned.
Methods
Tumor samples
Fifty-one pilocytic astrocytomas (PA) and 10 glioblastomas
(GBM) were included in this study. Among the 51 PA, 27
were located in the cerebellum, 17 in the H/C location
(optic pathway), 2 in the cerebral hemisphere, 3 in the me-
dulla and 2 in the brainstem. BRAF status (BRAFV600E
mutation and KIAA1549-BRAF fusion) was known for
38/51 [47]: 2/38 displayed BRAFV600E mutation and 29/38
PA displayed KIAA1549-BRAF fusion. Only one patient
was diagnosed with neurofibromatosis type 1 (NF1). Seven
pilomyxoid astrocytomas were included in this study: 2/7
from the cerebellum and 5/7 were from the H/C region.
Forty-four PA and 10 GBM were collected at our hospital
(Assistance Publique-Hôpitaux de Marseille, Marseille,
France) and 7 PA samples were obtained from the
Department of Pathology, University of Cambridge.
Mean age at diagnosis was 7 years for PA (range: 1 year
to 19 years, and a median age of 6 years) and mean age
at diagnosis was 60 years for GBM (range: 44 years to
73 years, and a median age of 59 years).
In addition, three PA specimens from posterior fossa
location, obtained from 3 additional young patients (6, 9
and 10 years old), were also used for explant culture.
BRAF status was also known for these tumor samples:
none of them displayed BRAFV600E mutation but they all
had KIAA1549-BRAF fusion gene.
Tumor specimens were obtained after written consent
and according to a protocol approved by the local institu-
tional review board and ethics committee and conducted
according to national regulations. All frozen samples were
stored in the Assistance Publique-Hôpitaux de Marseille
tumor bank (authorization number 2008–70). Histological
review of the frozen samples (DFB) confirmed the neo-
plastic nature of the tissue and demonstrated lack of
normal residual tissue in samples used for RT-Q-PCR
techniques.
RNA extraction
Total RNA was extracted using TRI Reagent (Sigma-
Aldrich, Paris, France), an improved version of the
single-step total RNA isolation reagent developed by
Table 2 Sequence of primers used in RT-Q-PCR
Name Sequence Size/bp
18S F : 5’-CTACCACATCCAAGGAAGGCA-3’ 71
R : 5’-TTTTTCGTCACTACCTCCCCG-3’
GAPDH F : 5’-CAAATTCCATGGCACCGTC-3’ 101
R : 5’-CCCACTTGATTTTGGAGGGA-3’
β-actin F : 5’-CCACACTGTGCCCATCTACG-3’ 99
R : 5’-AGGATCTTCATGAGGTAGTCAGTCAG-3’
CD36 F : 5'-TGCAAGTCCTGATGTTTCAGA-3' 142
R : 5'-TGGCTTGACCAATAGGTTGAC-3'
IQGAP1 F : 5'-AGAACAGACCAGATACAAGGCGA–3' 97
R : 5'-CTTAGGCAATCCAATCTCATCCA-3'
CRK F : 5'-GGAGTGATTCTCAGGCAGGA-3' 113
R : 5'-TCCCGGATTCTCAAGATGTC-3'
ICAM1 F : 5'-AGCTTCTCCTGCTCTGCAAC-3' 153
R : 5'-CATTGGAGTCTGCTGGGAAT-3'
COX-2 QUANTITECT (REF :QT00040586) 68
Forward (F)/Reverse (R) primers and size of corresponding amplified fragment
for each gene are listed. PCR conditions were as follows: 10 min at 95°C,
followed by 45 cycles of 15 s at 95°C, 30 s at 60°C for CD36, ICAM1, IQGAP1,
CRK and COX-2, 10 min at 95°C, followed by 30 cycles of 15 s at 95°C, 30 s at
67°C for 18S and 10 min at 95°C, followed by 45 cycles of 15 s at 95°C, 20 s at
65°C for GAPDH and β-actin.
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Chomczynski and Sacchi [48], according to the manufac-
turer’s instructions. RNA was analyzed on the spectropho-
tometer Nanodrop and Agilent 2100 bioanalyzer (Agilent
Technologies, Massy, France). Only samples with no evi-
dence of ribosomal peak degradation and RIN values ran-
ging between 8.0 and 10.0 were considered as high quality
intact RNA. Before use, RNA samples were treated with
1U ribonuclease-free deoxyribonuclease (Roche Applied
Science, Meylan, France) at 37°C for 20 min.
Total RNA (1 μg) DNA-free was reverse-transcribed into
cDNA using 1 μg of random hexamers and Superscript II
reverse transcriptase as recommended by the manufacturer
(Invitrogen Life Technologies, Cergy Pontoise, France).
Real-time quantitative PCR (RT-Q-PCR)
All PA and GBM samples were processed for the RT-Q-
PCR experiment using a LightCycler 480 (Roche Applied
Science) and the LightCycler 480 SYBR Green I Master
Mix (Roche Applied Science). The relative expression
ratio of the target mRNA and reference RNA (18S,
GAPDH, β-actin) was calculated using Q-PCR efficiencies
and the crossing point Cp deviation of a tumor sample
versus normal adult human brain (Agilent Technologies)
used as a control tissue [49]. Results are expressed as
median (interquartile range). Forward and reverse primers
for each gene are listed in Table 2.
GBM cell lines
The human U87-MG and U118 GBM cell lines (American
Type Culture Collection, Rockville, MD, USA) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% foetal calf serum (FCS), 50 U/ml
penicillin, 50 μg/ml streptomycin and 5 mM sodium pyru-
vate (all purchased at Invitrogen Life Technologies) and
they were maintained at 37°C in a 5% CO2 and 95% air
atmosphere.
Cell viability assay on GBM cell lines
Celecoxib (Sigma-Aldrich) was reconstituted in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich) and fluvastatin
(Sigma-Aldrich) in sterile water then diluted in culture
media before use.
Cytotoxic effect of celecoxib and/or fluvastatin on U87-
MG and U118 cell lines was evaluated by assessing cell
metabolic capacity, which reflects viability, using the MTT
kit (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, Sigma-Aldrich). The assays were conducted in
quadruplicate with blank controls containing culture media
only.
U87-MG and U118 cell lines (3.103 cells/well) were
seeded in 96-well plates. After 48 hr (subconfluency),
cells were treated with serial concentrations of
fluvastatin (30; 60; 120; 240; 365; 490; 610; 730; 850;
975 μM), celecoxib (0; 26; 52; 65; 78; 91; 104; 117; 131;
183; 210; 236; 260; 288; 314 μM) and their combinations
in 100 μl of culture media. In both cell lines, the concen-
trations of fluvastatin in combined treatments tested
were 240 and 480 μM and the concentrations of
celecoxib were 50, 80, 100, 130 and 260 μM.
At 48 h after treatment, 10 μl of MTT reagent (1/10)
was added to each well and incubated for 4 h at 37°C.
Then, the reduced formazan crystals were dissolved in
iso-propanol and absorbance was measured at 562 nm
on a microtiter ELISA plate reader. The cell growth in-
hibitory activity was obtained by subtracting the absorb-
ance of the blank controls and expressed as percentage
of cell growth inhibition as compared to untreated con-
trols (medium and drug diluents).
The IC50 values of both drugs for the 2 GBM cell lines
were determined. Then, synergistic interaction between
fluvastatin and celecoxib was analysed using the combin-
ation index (CI) values that were calculated with the
Calcusyn software based on the Chou and Talalay
method [50]. The CI theorem provides quantitative
definition for additive effects (CI=1), synergisms (CI<1)
and antagonisms (CI>1) in drug combinations.
Cell cycle analysis
Cell cycle analysis was performed by PI staining of
permeabilized cells and flow cytometry (FACS Calibur;
BD Biosciences). A total of 10 000 events were counted
for each sample. Data were analyzed with FlowJo soft-
ware (Celeza GmbH, Olten, Switzerland) choosing the
Dean-Jet-Fox model analysis.
KI67 staining
Quantification of cell proliferation was performed by KI67
staining. After permeabilization, cells were incubated with
KI67 antibody (1/25) (Dako, Glostrup) for 30 min at 4°C.
Then, cells were incubated with the secondary antibody
(anti-mouse IgG FITC, 1/100) (Jackson immunoresearch,
West Grove, USA). Cells were analysed by flow cytometry
(FACS Calibur; BD Biosciences) and data were analyzed
using CellQuest Pro analysis software.
Annexin V/PI double staining
Apoptotic cells were quantified by Annexin V/PI double
staining assay using the FITC Annexin V Apoptosis
Detection Kit (BD Biosciences, Le Pont de Claix, France)
as recommended by the manufacturer. The cells were
analysed by flow cytometry using a FACS Calibur flow
cytometer (BD Biosciences) within 1 hour and data were
analyzed by CellQuest Pro analysis software.
Establishment of PA explant cultures
Three PA samples named PA-NAV, PA-GAS and PA-PET
were collected after surgery in DMEM supplemented with
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10% FCS, 50 U/ml penicillin, 50 μg/ml streptomycin and
5 mM sodium pyruvate (all purchased at Invitrogen Life
Technologies). Tumors were processed as previously
described [25]. Briefly, tissues were washed, dissected,
automatically sectioned using a McIlwain tissue chopper
(Campden Instruments, Loughborough, England) and cut
into 500-μm3 pieces in DMEM 10% FCS, and plated on
glass coverslips (12-mm diameter) precoated with poly-
(L)-lysine (10 μg/ml, Sigma-Aldrich). The explant pieces
were maintained in DMEM 10% FCS. Medium was
supplemented with 0.4% methylcellulose (Sigma-Aldrich).
Explant cultures were incubated at 37°C in a 5% CO2 and
95% air atmosphere during maximum 40 days and were
fed every 3 days. Expression of GFAP and A2B5 were sys-
tematically analyzed on culture explants by immunofluor-
escent staining, as previously described [25] in order to
confirm the glial nature of cultured cells.
Cell viability assay on PA explant cells
Cytotoxic effect of celecoxib and fluvastatin and syner-
gistic interaction between both drugs were tested on PA
explants from PA-NAV, PA-GAS and PA-PET. Briefly,
after 10 days of culture, explants were treated with
fluvastatin (240 μM), celecoxib (100 μM) and their com-
bination (celecoxib 100 μM + fluvastatin 240 μM). At
48 h after treatment, explant cultures behavior was ana-
lyzed by phase contrast microscopy (Leica).
Statistical analysis
The association of the results of RT-Q-PCR with diagnosis
(H/C PA versus cerebellar PA and PA versus GBM) and
KI67 quantification was assessed by the non parametric
Mann–Whitney test using IBM SPSS PASW statistics
17.0. A p value <0.05 was considered significant.
Additional file
Additional file 1: Relative expression ratio values of the target
mRNA ICAM1, CRK, CD36 and IQGAP1 were calculated using
reference mRNA (18S, GAPDH, β-actin), RT-Q-PCR efficiencies and
the crossing point Cp deviation of a tumor sample versus normal
adult human brain used as a control tissue. Median, 25% quartile (Q1)
and 75% quartile (Q3) values were calculated for (a) hypothalamo-
chiasmatic pilocytic astrocytomas (H/C PA, n = 17) and cerebellar PA
(n = 27), and for (b) glioblastomas (GBM, n = 10) and PA (n = 51). (c) Raw
relative expression ratio values of the target mRNA were obtained for
U87-MG and U118 cell lines, PA-NAV, PA-GAS and PA-PET initial tumor
specimen and in the excised tumor of the case report.
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